Goldenwell Biotech, Inc.
OTC: GWLL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Shuang Liu
- Employees
- 3
- Headquarters
- Hudson, United States
- IPO year
- 2022
- Market cap
- $51.5M
- Website
- https://www.goldenwellbiotech.com
Loading GWLL…
Loading profile data…Frequently asked questions about GWLL
What does Goldenwell Biotech, Inc. (GWLL) do?
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was inc...
Where does GWLL trade?
Goldenwell Biotech, Inc. (GWLL) trades on the Other OTC.
What sector is GWLL in?
Goldenwell Biotech, Inc. (GWLL) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Goldenwell Biotech, Inc.?
Shuang Liu is the chief executive officer of Goldenwell Biotech, Inc. (GWLL).
Where is Goldenwell Biotech, Inc. headquartered?
Goldenwell Biotech, Inc. is headquartered in United States.
Does GWLL pay a dividend?
Goldenwell Biotech, Inc. (GWLL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GWLL go public?
Goldenwell Biotech, Inc. (GWLL) completed its initial public offering in 2022.